Surrozen Inc (SRZN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.76+0.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SRZN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 11.5 | 3.5 | 10.7 | 0.0 | 12.5 | 0.0 | — |
| Total Revenues | 11.5 | 3.5 | 10.7 | 0.0 | — | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 34.6 | 29.4 | 21.1 | 27.2 | 37.0 | 40.2 | 25.7 |
| Operating Income | (44.4) | (42.1) | (25.5) | (45.8) | (44.3) | (54.4) | (32.8) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 3.5 | 3.0 | 1.7 | 2.3 | 0.8 | 0.1 | 0.1 |
| Asset Writedown | — | — | — | 0.1 | — | — | — |
| EBT, Incl. Unusual Items | — | (242.0) | — | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (332.1) | (242.0) | (63.6) | (43.0) | (36.0) | (54.6) | (32.7) |
| Per Share | |||||||
| Basic EPS | (28.48) | (32.37) | (21.67) | (21.33) | (15.56) | (2.21) | — |
| Diluted EPS | (14.35) | (32.37) | (21.67) | (21.33) | (15.56) | (2.21) | — |
| Revenue per Share | 0.50 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 11.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Diluted Weighted Avg Shares | 23.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Supplemental | |||||||
| EBITDA | — | (41.6) | (24.1) | (43.9) | (42.4) | (52.3) | (30.9) |
| EBIT | (44.4) | (42.1) | (25.5) | (45.8) | (44.3) | (54.4) | (32.8) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.